EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion

Songji Choi, Miso Kim, Sheehyun Kim, Taekeun Park, Yoonjin Kwak, Jeong Mo Bae, Hongseok Yun, Jee Hyun Kim

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.1184 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Songji Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Oncogene Proteins, Fusion, Neoplasms, Muscle Tissue, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory myofibroblastic tumor (IMT) is a rare entity, primarily affecting young individuals, often involving the abdomen, pelvis, or lung. Approximately 50% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangements, making ALK inhibitors a viable treatment. We report a case of a 40-year-old female with metastatic IMT harboring a CARS1-ALK fusion. Initial chemotherapy failed, but targeted therapy with alectinib through the KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study led to significant tumor regression and ongoing, durable clinical improvement of 19 months. This case highlights the importance of precision medicine and raises the reappraisal of targeted agents outside of approved indications for rare cancers with actionable genomic alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseOncogene Proteins, FusionNeoplasms, Muscle TissueProtein Kinase InhibitorsReceptors, Chimeric AntigenCarbazolesPiperidinesHumansFemaleAdultTreatment Outcome

Stichwörter der Autor:innen

ALK fusionAlectinibInflammatory myofibroblastic tumorPrecision medicine

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsReceptors, Chimeric AntigenalectinibCarbazolesPiperidines

Autor:innen und Institutionen

  • Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Department of Genomic Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Förderung

  • Ministry of Health and Welfare

Zitieren

APA

Choi, S., Kim, M., Kim, S., Park, T., Kwak, Y., Bae, J. M., Yun, H., & Kim, J. H. (2025). ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.1184

Vancouver

Choi S, Kim M, Kim S, Park T, Kwak Y, Bae JM, et al. ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.1184

BibTeX
@article{Choi2025,
  author = {Choi, Songji and Kim, Miso and Kim, Sheehyun and Park, Taekeun and Kwak, Yoonjin and Bae, Jeong Mo and Yun, Hongseok and Kim, Jee Hyun},
  title = {ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.1184}
}
Kostenlos starten →